<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906347</url>
  </required_header>
  <id_info>
    <org_study_id>102008-030</org_study_id>
    <nct_id>NCT00906347</nct_id>
  </id_info>
  <brief_title>A Trial of Oral Misoprostol for Labor Augmentation</brief_title>
  <official_title>A Randomized, Controlled Trial of Oral Misoprostol for Labor Augmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled trial designed to examine the efficacy of oral
      misoprostol for labor augmentation compared to a standard regimen of intravenous oxytocin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine Tachysystole</measure>
    <time_frame>Up to four hours after administration of study drug</time_frame>
    <description>Defined as six contractions in two consecutive 10-minute periods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infant Apgar Score &lt;4</measure>
    <time_frame>5 minutes after delivery</time_frame>
    <description>Assigned on a scale of 0-10 by pediatric provider attending delivery. A lower score reflects need for further resuscitation and is potentially associated with increased risk of adverse neurological outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Artery pH &lt;7.1</measure>
    <time_frame>Obtained at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission of Neonatal Intensive Care Unit</measure>
    <time_frame>Until hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Chorioamnionitis</measure>
    <time_frame>During labor</time_frame>
    <description>Temperature 38 degrees C or higher in the absence of other sources of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Hypovolemia Requiring Blood Transfusion</measure>
    <time_frame>Until hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Method of Delivery</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Elapsed From Start of Labor Augmentation to Delivery</measure>
    <time_frame>Initiation of augmentation until delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Labor Augmentation</condition>
  <arm_group>
    <arm_group_label>Oxytocin augmentation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol augmentation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>75 micrograms orally every 4 hours for up to 2 doses.</description>
    <arm_group_label>Misoprostol augmentation</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
    <arm_group_label>Oxytocin augmentation</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical decision to augment labor

          -  Gestational age &gt; than or equal to 36 weeks

          -  Singleton gestation

          -  Cephalic presentation

          -  Reassuring fetal heart rate tracing

          -  Cervical dilation between 4 and 8 cm

          -  Ruptured membranes with clear amniotic fluid

          -  Intrauterine pressure catheter in place

          -  Less than 200 MVUs in a 10 minute period

          -  5 or fewer contractions in a 10 minute period

          -  English or Spanish speaking patient

        Exclusion Criteria:

          -  Non-reassuring fetal heart rate tracing at time of enrollment

          -  Meconium stained amniotic fluid

          -  Previous uterine incision

          -  Maternal fever (defined as greater than 37.9 C)

          -  Known fetal anomalies

          -  Placenta previa or unexplained vaginal bleeding

          -  Estimated fetal weight of 4,500 grams or more

          -  Abnormal maternal bony pelvis

          -  Grandmultiparity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>April Bleich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Leveno, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <results_first_submitted>October 5, 2012</results_first_submitted>
  <results_first_submitted_qc>October 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Labor augmentation</keyword>
  <keyword>Oral misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women presenting to Labor and Delivery at Parkland Memorial Hosiptal and who met eligibility requirements were offered participation from Decemeber 2008 through January 2001.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
        </group>
        <group group_id="P2">
          <title>Oxytocin Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Received Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>8 cm prior to initiation of study drug</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nonreassuring fetal heart rate</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uterine tachysystole or hypertonus</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
        </group>
        <group group_id="B2">
          <title>Oxytocin Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="5.8"/>
                    <measurement group_id="B2" value="24.1" spread="5.3"/>
                    <measurement group_id="B3" value="24.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Uterine Tachysystole</title>
        <description>Defined as six contractions in two consecutive 10-minute periods</description>
        <time_frame>Up to four hours after administration of study drug</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Tachysystole</title>
          <description>Defined as six contractions in two consecutive 10-minute periods</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Apgar Score &lt;4</title>
        <description>Assigned on a scale of 0-10 by pediatric provider attending delivery. A lower score reflects need for further resuscitation and is potentially associated with increased risk of adverse neurological outcomes.</description>
        <time_frame>5 minutes after delivery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Apgar Score &lt;4</title>
          <description>Assigned on a scale of 0-10 by pediatric provider attending delivery. A lower score reflects need for further resuscitation and is potentially associated with increased risk of adverse neurological outcomes.</description>
          <population>Intent to treat</population>
          <units>infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Umbilical Cord Artery pH &lt;7.1</title>
        <time_frame>Obtained at delivery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Umbilical Cord Artery pH &lt;7.1</title>
          <population>Intent to treat</population>
          <units>infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Admission of Neonatal Intensive Care Unit</title>
        <time_frame>Until hospital discharge</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Admission of Neonatal Intensive Care Unit</title>
          <population>Intent to treat</population>
          <units>infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Chorioamnionitis</title>
        <description>Temperature 38 degrees C or higher in the absence of other sources of infection</description>
        <time_frame>During labor</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Chorioamnionitis</title>
          <description>Temperature 38 degrees C or higher in the absence of other sources of infection</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Hypovolemia Requiring Blood Transfusion</title>
        <time_frame>Until hospital discharge</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Hypovolemia Requiring Blood Transfusion</title>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Method of Delivery</title>
        <time_frame>At delivery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Method of Delivery</title>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spontaneous vaginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forceps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cesarean for dystocia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cesarean for nonreassuring fetal heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Elapsed From Start of Labor Augmentation to Delivery</title>
        <time_frame>Initiation of augmentation until delivery</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Augmentation</title>
            <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Time Elapsed From Start of Labor Augmentation to Delivery</title>
          <population>Intent to treat</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306" lower_limit="150" upper_limit="534"/>
                    <measurement group_id="O2" value="276" lower_limit="162" upper_limit="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.</description>
        </group>
        <group group_id="E2">
          <title>Oxytocin Augmentation</title>
          <description>Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Need for emergent cesarean delivery secondary to nonreassuirng fetal heart rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. April Bleich</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-2316</phone>
      <email>april.bleich@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

